<DOC>
	<DOCNO>NCT02660905</DOCNO>
	<brief_summary>This prospective open label pilot study conduct 32 week . A total 25 eligible participant infect HCV HIV recruit 2 Canadian HIV Trials Network ( CTN ) sit ( Ottawa Hospital Research Institute McGill University Health Centre ) This study look effectiveness combination Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide Single Tablet Regimen ( E/C/F/TAF STR ) HIV treatment Harvoni HCV treatment . This study ass effect study drug metabolism sugar , change fat bloodstream metabolic change . Metabolism process body use get make energy food eat . This study may provide information impact liver fibrosis ( scar liver tissue ) metabolic change , HCV antiviral therapy . Drug-drug interaction ( DDI ) DDI E/C/F/TAF LPV-SOF well evaluate clinically significant interaction identify . A switch E/C/F/TAF context LPV-SOF HCV antiviral treatment preparation may particularly beneficial : 1. favorable side effect profile 2. daily STR formulation 3. know DDI profile LPV-SOF 4. neutral effect liver fibrosis 5. improved kidney bone safety profile use TAF Conduct study justify : 1 . Assesses minimal pill count dose frequency strategy co-treatment HIV HCV use well tolerate medication excellent safety profile know DDI profile . 2 . Provides additional safety data TAF HIV-HCV co-infected population . 3 . Quantifies adherence identifies obstacles full adherence population . There paucity data relate DAA adherence licensing study . 4 . Provides real-world safety efficacy data support public funding LPV-SOF DAA therapy HIV-HCV co-infected population . 5 . Provides preliminary data immunologic metabolic consequence HCV clearance HIV-HCV co-infection 6 . As pilot study , information gather inform feasibility future clinical trial evaluate novel treatment strategy HIV-HCV co-infected patient .</brief_summary>
	<brief_title>HIV Drug Switch Followed HCV Therapy HIV-HCV Co-Infection</brief_title>
	<detailed_description>The availability interferon ( IFN ) -free HCV Direct Acting Antiviral ( DAA ) antiviral therapy Ledipasvir-Sofosbuvir ( LPV-SOF ) allow broad provision treatment population live HIV-HCV . Co-infected person frequently compete co-morbidities risk progressive liver disease make adherence combined management HIV HCV challenge . Simple , safe , well tolerate regimens drug-drug interaction could highly beneficial ensure success HCV therapy population . With mind , optimal management antiretroviral therapy prior initiate LPV-SOF treatment remain unclear . E/C/F/TAF [ elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide fumerate ( TAF ) ] assess study formulate single tablet facilitates adherence daily dosing reduce pill count . It establish affective achieve maintain HIV virologic suppression . The safety profile HIV regimen excellent . The E/C/F/TAF formulation assess study contain TAF . This formulation evaluate HIV-infected population find equivalent HIV antiviral activity improve impact renal bone metabolism [ ref : David Wohl , Anton Pozniak , Melanie Thompson , Edwin DeJesus , Daniel Podzamczer , Jean-Michel Molina , Gordon Crofoot , Christian Callebaut , Hal Martin , Scott McCallister . Tenofovir Alafenamide ( TAF ) Single-Tablet Regimen Initial HIV-1 Therapy . Conference Retroviruses Opportunistic Infections . 113LB . February 23-26 , 2015 , Seattle , Washington. ] . There minimal safety data HIV-HCV co-infection . Drug-drug interaction ( DDI ) HIV antiretrovirals HCV antiviral remain key obstacle safe effective delivery . The DDI E/C/F/TAF LPV-SOF well evaluate clinically significant interaction identify . A switch E/C/F/TAF context LPV-SOF HCV antiviral treatment preparation may particularly beneficial : 1. favorable side effect profile 2. daily STR formulation 3. know DDI profile LPV-SOF 4. neutral effect liver fibrosis 5. improved kidney bone safety profile use TAF Conduct study justify : 1 . Assesses minimal pill count dose frequency strategy co-treatment HIV HCV use well tolerate medication excellent safety profile know DDI profile ( Complera follow LPV-SOF ) . Polypharmacy co-infected population remain significant challenge therapeutic success . 2 . Provides additional safety data TAF HIV-HCV co-infected population . 3 . Quantifies adherence identifies obstacles full adherence population . There paucity data relate DAA adherence licensing study . 4 . Provides real-world safety efficacy data support public funding LPV-SOF DAA therapy HIV-HCV co-infected population . 5 . Provides preliminary data immunologic metabolic consequence HCV clearance HIV-HCV co-infection 6 . As pilot study , information gather inform feasibility future clinical trial evaluate novel treatment strategy HIV-HCV co-infected patient .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Coinfection</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir , sofosbuvir drug combination</mesh_term>
	<criteria>Inclusion HIV infect ( ELISA western blot confirmation ) HCV RNA positive minimum 6 month / Genotype 1 Prescribed cART may include DHHS recommend alternative regimen , treat physician considers , appropriate patient . ( We anticipate approximately 60 % HIV protease inhibitorbased regimen ) . HIV RNA BLLQ minimum 3 month Stage 0 4 fibrosis No evidence liver decompensation define past current ascites , bleed varix hepatic encephalopathy . Prior interferon , ribavirin and/or HCV protease inhibitor exposure allow exception cirrhotic past history null response interferonbased therapy . Ability remain adherent medication study protocol per investigator opinion For female subject , pregnant , plan suspect pregnant breastfeed Willing use acceptable method birth control , define protocol Active substance use and/or mental health issue exclusionary assume criterion meet . This inclusion restrict stably house engage harm reduction strategy . Our intent evaluate study participant representative clinical population consider 'difficult cure ' compare population already evaluate license study Exclusion : Concomitant use drug contraindication drug interaction E/C/F/TAF SOFLDV History HIV integrase inihbitors NRTI resistance mutation Platelets &lt; 50 x109/L</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>HIV-HCV co-infected</keyword>
	<keyword>HCV</keyword>
	<keyword>HIV</keyword>
	<keyword>Hep C</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV positive</keyword>
</DOC>